Shilpa Medicare Ltd reports a strong 1QFY27 with revenue up 43% YoY and EBITDA growing 42%, driven by robust performance across its key verticals.
Shilpa Medicare Limited (NSE: SHILPAMED) stock moves up 5% intraday, approaching resistance at ₹635. The stock is 0.
Shilpa Medicare Limited (NSE: SHILPAMED) stock moves up 5% intraday, approaching resistance at ₹623, backed by partnership expansion with Orion Corporation f.
Shilpa Medicare Limited (NSE: SHILPAMED) is down 5% intraday at ₹565.0, showing pressure after breakout.
Shilpa Medicare Limited (NSE: SHILPAMED) stock breaks out, gaining 5% intraday to ₹605.0, backed by expanded partnership with Orion Corporation for Nivolumab.
Shilpa Medicare Limited (NSE: SHILPAMED) announces expanded partnership with Orion Corporation for developing and supplying nivolumab biosimilar in Europe.
Shilpa Medicare Limited (NSE: SHILPAMED) announced the commissioning of an advanced ADC Drug Substance GMP facility in Dharwad, India.
